Advancements in Bladder Cancer
1 hour video discussion focusing on case studies in bladder cancer
Acknowledgements
Support provided by independent educational grants from:
- Astellas and Pfizer, Inc.
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Merck & Co., Inc.
Target Audience
- JUA Young Urologists
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Discuss risk stratification of patients with NMIBC, including important features and available stratification tools, as well as management strategies based on assigned risk
- Characterize available treatments for patients with BCG unresponsive NMIBC
- Discuss guideline-based management options for patients with non-metastatic, muscle invasive bladder cancer
Pre-test
Welcome and Introductions
Segment 1: Risk Stratification
Segment 2: BCG-unresponsive Bladder Cancer
Segment 3: Current best practices for non-metastatic MIBC
Wrap-up
Post-test
Faculty Disclosures
Name | Company Name | Relationship Type | End Date |
Nishiyama, Hiroyuki | Merck Sharp & Dohme (MSD) | Meeting Participant or Lecturer | Current |
Nishiyama, Hiroyuki | Astellas | Meeting Participant or Lecturer | Current |
Nishiyama, Hiroyuki | AstraZeneca | Meeting Participant or Lecturer | Current |
Nishiyama, Hiroyuki | Nippon Kayaku Co.Ltd | Meeting Participant or Lecturer | Current |
Nishiyama, Hiroyuki | Ono Pharmaceutical | Meeting Participant or Lecturer | Current |
Nishiyama, Hiroyuki | Bristol Myers Squibb (BMS) | Meeting Participant or Lecturer | Current |
Nishiyama, Hiroyuki | Merck Biopharma Co.Ltd. | Meeting Participant or Lecturer | Current |
Nishiyama, Hiroyuki | Chugai Pharma | Other-Contract research | Current |
Nishiyama, Hiroyuki | Ono Pharmaceutical | Consultant or Advisor | Current |
Nishiyama, Hiroyuki | AstraZeneca | Consultant or Advisor | Current |
Nishiyama, Hiroyuki | Merck Sharp & Dohme (MSD) | Consultant or Advisor | Current |
Nishiyama, Hiroyuki | Janssen.com | Consultant or Advisor | Current |
Porten, Sima Prabodh | Photocure | Scientific Study or Trial | Current |
Porten, Sima Prabodh | Stryker | Consultant or Advisor | Current |
Porten, Sima Prabodh | AstraZeneca | Consultant or Advisor | Current |
Porten, Sima Prabodh | Pacific Edge | Consultant or Advisor | Current |
Scarpato, Kristen R. | CxBladder | Scientific Study or Trial | Current |
Education Council Disclosures
Education Council Disclosures_2024_01_25_2.pdf
COI Review Work Group Disclosures
COI Review Work Group Disclosures.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pre-test, viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.00 hours
Release Date: February, 2024
Expiration Date: March 09, 2027
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
DISCLAIMER:
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
REPRODUCTION PERMISSION:
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation